MIR Preclinical Services Offers Preclinical Models of Collagen Antibody Induced Arthritis

ANN ARBOR, Mich., June 24, 2008 (PRIME NEWSWIRE) -- MIR Preclinical Services (MIR) has added a preclinical model of Collagen Antibody Induced Arthritis (CAIA) to its list of in vivo service offerings. CAIA is a model of human rheumatoid arthritis that has the advantage of inducing disease in mouse strains that are resistant to the traditional collagen induced models. CAIA relies on the injection of a cocktail of monoclonal antibodies directed against type II collagen followed by a single injection of LPS. Disease begins to appear within 7-8 days in this model as opposed to 21-28 days in the traditional method of disease induction. A typical Collagen Antibody Induced Arthritis study can be completed within 18-24 days.